Patents by Inventor Ulta Mandel

Ulta Mandel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9588121
    Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilizing a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualization and treatment of specific cancer types.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: March 7, 2017
    Assignee: GO THERAPEUTICS, INC.
    Inventors: Hans H. Wandall, Johannes W. Pedersen, Eric P. Bennett, Henrik Clausen, Ulta Mandel
  • Publication number: 20130059744
    Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.
    Type: Application
    Filed: November 5, 2010
    Publication date: March 7, 2013
    Inventors: Hans H. Wandall, Johannes W. Pedersen, Eric P. Bennett, Henrik Clausen, Ulta Mandel